Cancers (Aug 2022)

A miRNA-Based Prognostic Model to Trace Thyroid Cancer Recurrence

  • Eman A. Toraih,
  • Manal S. Fawzy,
  • Bo Ning,
  • Mourad Zerfaoui,
  • Youssef Errami,
  • Emmanuelle M. Ruiz,
  • Mohammad H. Hussein,
  • Muhib Haidari,
  • Melyssa Bratton,
  • Giovane G. Tortelote,
  • Sylvia Hilliard,
  • Naris Nilubol,
  • Jonathon O. Russell,
  • Mohamed A. Shama,
  • Samir S. El-Dahr,
  • Krzysztof Moroz,
  • Tony Hu,
  • Emad Kandil

DOI
https://doi.org/10.3390/cancers14174128
Journal volume & issue
Vol. 14, no. 17
p. 4128

Abstract

Read online

Papillary thyroid carcinomas (PTCs) account for most endocrine tumors; however, screening and diagnosing the recurrence of PTC remains a clinical challenge. Using microRNA sequencing (miR-seq) to explore miRNA expression profiles in PTC tissues and adjacent normal tissues, we aimed to determine which miRNAs may be associated with PTC recurrence and metastasis. Public databases such as TCGA and GEO were utilized for data sourcing and external validation, respectively, and miR-seq results were validated using quantitative real-time PCR (qRT-PCR). We found miR-145 to be significantly downregulated in tumor tissues and blood. Deregulation was significantly related to clinicopathological features of PTC patients including tumor size, lymph node metastasis, TNM stage, and recurrence. In silico data analysis showed that miR-145 can negatively regulate multiple genes in the TC signaling pathway and was associated with cell apoptosis, proliferation, stem cell differentiation, angiogenesis, and metastasis. Taken together, the current study suggests that miR-145 may be a biomarker for PTC recurrence. Further mechanistic studies are required to uncover its cellular roles in this regard.

Keywords